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ABSTRACT 
Incorporation rates of the enantiomers of 3,4-methylenedioxymethamphetamine 
(MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA) into hair and 
nails were investigated after controlled administration. Fifteen subjects without 
MDMA use received two doses of 125 mg of MDMA. Hair, nail scrapings and nail 
clippings were collected 9-77 days after the last administration (median: 20 days). 
Hair samples were analyzed in segments of 1- to 2-cm length. After chiral 
derivatization with N-(2,4-dinitro-5-fluorophenyl)-L-valinamide, MDMA and MDA 
diastereomers were analyzed by liquid chromatography-tandem mass spectrometry. 
Highest concentrations in hair segments corresponded to the time of MDMA intake. 
They ranged from 101 to 3,200 pg/mg and 71 to 860 pg/mg for R- and S-MDMA, and 
3.2 to 116 pg/mg and 4.4 to 108 pg/mg for R- and S-MDA, respectively. MDMA and 
MDA concentrations in nail scrapings and clippings were significantly lower than in 
hair samples. There was no significant difference between enantiomeric ratios of 
R/S-MDMA and R/S-MDA in hair and nail samples (medians: 2.2-2.4 for MDMA and 
0.85-0.95 for MDA). Metabolite concentration ratios of MDA to MDMA were in the 
same range in hair and nail samples (medians: 0.044-0.055). Our study 
demonstrates that administration of two representative doses of MDMA was detected 
in the hair segments corresponding to the time of intake based on average hair 
growth rates. MDMA was detected in all nail samples regardless of time passed after 
intake. Comparable R/S ratios in hair and nail samples may indicate that 
incorporation mechanisms for both matrices are comparable.  
Keywords: Hair analysis; nail analysis, MDMA enantiomers; controlled 
administration  
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Introduction 
The analysis of keratinzed matrices such as hair has achieved considerable 
importance in forensic toxicology. Main applications are long-term monitoring of drug 
and alcohol consumption, e.g. of drug abusers or dealers, in abstinence controls for 
regranting driver’s license, in postmortem investigations or in drug-facilitated crimes 
[1,2]. In some cases, it is necessary to evaluate whether an individual has taken the 
drug on a regular basis or whether a single or sporadic intake is more likely. In order 
to gain time-resolved information on an individual’s drug exposure, the Society of 
Hair Testing (SoHT) recommends analysis of hair segments of 1- to 3-cm [3]. Based 
on an average growth rate of 1 cm per month (range 0.7 – 1.4 cm per month) the 
time frame of drug intake can be estimated [1]. Several reports describe the detection 
of drug not only in hair segments corresponding to the expected time of 
intake/administration but also in adjacent segments [4-7]. This may render 
interpretation of analysis results difficult. For amphetamines, a positive correlation 
after controlled administration of a low and high dose of amphetamine and 
methamphetamine was demonstrated within subjects but not between subjects [8]. 
Nails, another keratinzed matrix, are being discussed as an alternative to hair 
because nails also accumulate drugs [9-15]. Investigations on paired hair and nail 
analysis for amphetamines delineated similar [16] or higher concentrations in hair 
[17], but one group reported slightly higher amphetamine concentrations in 
fingernails compared to hair [18].  
The exact mechanism for drug incorporation into hair and nails has not been 
identified [1,10]. It is nowadays recognized that drug disposition into hair takes place 
not only at the hair follicle but also via diffusion from sweat and sebum [1]. Studies on 
the incorporation pathways into nails were performed after a single dose of zolpidem 
[19,20]. The germinal nail matrix and nail bed were identified as incorporation regions 
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for drugs. Furthermore, sweat presumably contributes to a large extent to drug 
disposition into nail as drug could already be detected in fingernail clippings 24 hours 
after drug intake [20]. The investigation of drug stereoisomers could hypothetically 
provide insights into incorporation mechanisms into hair and nail. It is recognized that 
enantiomers can display significantly distinct pharmacokinetic and pharmacodynamic 
behavior implying differences in affinity to metabolizing enzymes or receptor sites 
[21].  
MDMA (3,4-methylenedioxymethamphetamine, ecstasy) is an illicit drug mostly 
traded as racemic mixture [22]. It belongs to the most prevalent drugs involved in 
forensic and driving under the influence cases [23-27]. MDMA is used for its 
entactogenic effects and stimulation of the central nervous system [28] which are 
mainly attributed to the S-MDMA enantiomer [29]. The R-enantiomer was reported to 
be more abundant in human tissues and fluids representing its enantioselective 
metabolism most likely because of the elimination of the S-enantiomer from plasma 
at a higher rate [30-33]. MDMA is primarily metabolized to 3,4-dihydroxymethamphet- 
amine (DHMA) by the cytochrome P450 isoenzyme CYP2D6 [29], which is 
polymorphic [34]. MDA (3,4-methylenedioxyamphetamine) is a minor metabolite of 
MDMA formed by N-demethylation [29].  
The present study aims at analyzing hair and nail samples for enantiomers of MDMA 
and its metabolite MDA after controlled administration of two doses of 125 mg of 
racemic MDMA. Segmental analysis of hair samples is performed to study whether 
drug detection in a hair segment can be correlated to the respective time period of 
MDMA intake. Nail samples are evaluated as an alternative specimen to hair when 
testing for single/sporadic MDMA intake. The enantioselective patterns of MDMA and 
MDA in hair and nails are examined to gain insights whether incorporation 
mechanisms into these matrices differ. To our knowledge, the present study is the 
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first report on the disposition of MDMA and MDA enantiomers in hair and nail 
samples of non-drug using participants following controlled intake of MDMA. 
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Experimental 
Study design and sample collection 
Hair and nail samples were obtained from a double-blind, placebo-controlled, cross-
over study performed at the University Hospital of Basel, Switzerland, to investigate 
pharmacokinetic effects of MDMA [35]. The study was conducted in accordance with 
the Declaration of Helsinki and International Conference on Harmonization 
Guidelines in Good Clinical Practice and approved by the Ethics Committee of the 
Canton of Basel, Switzerland, and the Swiss Agency for Therapeutic Products 
(Swissmedic). All participants provided written informed consent. Only subjects with 
no prior regular MDMA use were included. Five subjects had previously used MDMA 
(<5 times) at least 2 months prior to the study start. Drug use during the study was 
excluded using repeated urine tests [35]. Subjects (n=15) were administered two 
doses of pharmaceutical grade racemic MDMA (MDMA hydrochloride 125 mg) in 
capsules. The time interval between the two administrations was different for each 
subject ranging between 9 to 105 days (median: 18 days). Head hair samples, nail 
scrapings, and clippings were collected; 13 nail samples were from the ring finger 
and 3 from the big toe. Nails were wiped twice with acetone prior to sample 
collection. The time between last MDMA intake and sample collection ranged from 9 
to 77 days (median: 20 days). All subjects were pheno- and genotyped for CYP2D6 
activity [35]. Fourteen participants were extensive metabolizers and one participant 
(no. 1) was a poor metabolizer (Table 2). 
 
Materials 
Deuterated and undeuterated racemic standards were obtained as calibrated 
methanolic solutions from Lipomed (Arlesheim, Switzerland). N-(2,4-dinitro-5-
fluorophenyl)-L-valinamide (DNPV) for derivatization and all other chemicals were 
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purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). Solvents for 
washing, extraction and analysis by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), all of HPLC grade, were obtained from Sigma-Aldrich 
Chemie GmbH (Buchs, Switzerland). Drug-free hair and nail samples for method 
validation were provided by drug-naïve volunteers. 
 
Analytical methods  
Hair and nail sample preparation 
Hair samples were segmented in three 1-cm and one 2-cm-segments from proximal 
to distal. Hair segments were washed separately with 2 mL water and 2 mL acetone 
for 2 min, nail clippings were washed once with 1 mL water for 30 sec by vortexing. 
On average 20 mg hair segments, 5 mg clippings and 1-5 mg scrapings were used 
for analysis. Hair and nail clippings were pulverized at 25 Hz for 8 min using a mixer 
mill (MM 200 Retsch, Switzerland). For extraction, 0.1 mL IS solution (50 ng/mL) 
containing MDMA-d5 and MDA-d5 and 0.9 mL MeOH were added and samples were 
sonicated for 4 h. Extracts were filtered through a 0.22 um PTFE syringe filter (BGB, 
Boeckten, Switzerland) and 50 µL formic acid (20%, v/v) were added for evaporation 
at 50 °C under nitrogen. The residue was reconstituted in 80 µL carbonate buffer 
(1 M, pH 9). For derivatization of MDMA and MDA 30 µL 0.3 % N-(2,4-dinitro-5-
fluorophenyl)-L-valinamide (DNPV) in acetone were added and vials were placed in a 
heating block at 50 °C for 30 min as previously described [36,37]. Derivatization was 
stopped by the addition of 20 µL hydrochloric acid (1 M). After the addition of 30 µL 
mobile phase mixture (A: 25 M ammonium acetate buffer pH 4 containing 0.1 % of 
formic acid/B: acetonitrile containing 0.1 % of acetic acid; 1/1; v/v) diastereomers of 
derivatized MDMA and MDA were analyzed by LC-MS/MS.  
 
8 
LC-MS/MS parameters 
Analytes were separated on a Phenomenex Kinetex C18 column (100 x 2.1 mm, 
2.6 um) using a Thermo Fisher Ultimate 3000 high performance liquid 
chromatography (UHPLC) system and detected by an Applied Biosystems 5500 Q 
Trap linear ion trap triple quadrupole mass spectrometer (Sciex, Darmstadt/ 
Germany) with Analyst software (Version 1.6). The following mobile phase gradient 
of eluent A and B was adjusted: 0-1 min: 2% B; 1-2 min: increase to 40% B;  2-9.3 
min: increase to 60% B; 9.3-9.5 min: increase to 98% B; 9.5-10.5 min: holding at 
98% B; 10.5-10.8 min: decrease to 2% B; 10.8-12 min: holding at 2% B. The flow 
rate was 0.4 mL/min. The column temperature was maintained at 35°C and the 
injection volume was 10 µL. The MS instrument was operated in positive electrospray 
ionization and multiple reaction monitoring mode. Quantification was achieved using 
the most abundant transition of each precursor to the respective product ion and two 
MRM transitions served for identification. Further MS operation parameters were as 
previously reported by Steuer et al. [36]. 
 
Method validation 
Standard solutions of racemic MDMA and MDA for six calibrators and quality controls 
(QC) at two concentration levels, low and high, were prepared separately by diluting 
the respective stock solution with acetonitrile. Concentrations are given in Table 1. 
An internal standard solution of racemic MDMA-d5 and MDA-d5 in acetonitrile was 
prepared at a concentration of 50 ng/mL. Blank matrix of 20 mg hair and 5 mg nail 
were spiked with 100 uL of each calibrator or QC solution. Calibration curves and 
quality control samples (in duplicate) were analyzed on five days. Quantitation was 
performed by determining the analyte to IS peak area ratios. A weighted linear 
regression model (1/concentration) was applied. The lower limit of quantification 
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(LLOQ) and limit of detection (LOD) was chosen to be the concentration resulting in a 
peak height with a signal-to-noise ratio of 10 and 3, respectively. Matrix effects were 
studied according to Matuszewski et al. [38]. The method was validated according to 
international guidelines[39]. 
 
Data analysis 
Statistical analyses were carried out with Prism 6 (GraphPad Software, La Jolla, CA, 
USA). The nonparametric two-sided Wilcoxon matched pairs rank signed test was 
utilized for comparison of paired nail and hair samples results because no Gaussian 
distribution was observed. P values between 0.001–0.01 were considered as very 
significantly different, 0.01–0.05 as significantly different, p values above 0.05 were 
not significant. 
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Results 
Method validation 
The method was validated based on the Guidelines for Quality Control in Forensic-
Toxicological Analyses of the GTFCh for the criteria selectivity, LOD, LLOQ, linearity 
of calibration, accuracy, repeatability, precision, and matrix effects [39]. Validation 
data are given in Table 1. Calibration curves were linear over the concentration range 
of 0.5 to 500 pg/mg for hair samples and 2.0 to 2000 pg/mg for nail samples. The 
criteria for accuracy, repeatability and precision were fulfilled. In case of S-MDMA, 
the deuterated analogue as IS should compensate for matrix effects which were 
slightly above the acceptable threshold (Table 1).  
 
Study samples 
Hair specimens were obtained from 13 participants. Hair samples were analyzed in 
segments of 1 + 1 + 1 + 2 cm length from proximal to distal. All subjects (n=15) 
provided nail samples; 13 clippings from fingernails and three from toenails, and 12 
scrapings from fingernails and two from toenails were collected, respectively. All 
samples were tested for MDMA and MDA enantiomers. The sum of MDA and MDMA 
enantiomers, respectively, was calculated. Concentrations for 5-cm-hair segments 
were calculated as an average of the four hair segments considering segment 
lengths. Concentrations of MDMA and MDA enantiomers and their sum in all 
samples are given in Figure 1 and Table 2, respectively. 
 
MDMA and MDA in hair samples 
All hair segments were tested positive for MDMA and MDA enantiomers. R- and S-
MDMA concentrations ranged from 101 to approximately 3,200 pg/mg (median: 470 
pg/mg) and 71 to approximately 860 pg/mg (median: 221 pg/mg), respectively 
11 
(Figure 1A, B). The highest R-MDMA concentration (identified as outlier by Grubbs’ 
test, α< 0.01) was observed in the hair sample of participant no. 1 who was 
henotyped a CYP2D6 poor metabolizer. R-MDMA was detected to a significantly 
higher extent into hair than S-MDMA (Figure 1A) whereas no difference was 
observed for MDA enantiomers (Figure 1B). R- and S-MDA concentrations ranged 
from 3.2 to 116 pg/mg (median: 21 pg/mg) and 4.4 to 108 pg/mg (median: 14 pg/mg), 
respectively (Figure 1B).  
In all cases, the highest concentration of each MDMA and MDA enantiomer was 
found in hair segments corresponding to the time of MDMA intake based on an 
average hair growth rate of 1 cm per month. Accordingly, concentrations of the sum 
of MDMA enantiomers in hair segments corresponding to the time of intake ranged 
from 173 to 3’770 pg/mg (median: 694 pg/mg). The sum of concentrations of MDMA 
enantiomers in the four hair segments and the time of MDMA intake are presented in 
Figure 2. In all samples MDMA and MDA could also be detected in hair segments 
adjacent to the one corresponding to time of intake, however, at much lower levels. 
Calculated concentrations of the sum of MDMA and MDA enantiomers, respectively, 
in 5-cm-segments varied from 78 to 850 pg/mg (median: 370 pg/mg) and 3.9 to 46 
pg/mg (median: 19 pg/mg), respectively (Table 2).  
 
MDMA and MDA in nail samples 
All nail clippings were tested positive for MDMA and MDA enantiomers regardless of 
time past MDMA intake (Table 2) (Figure 1C-F). R- and S-MDMA concentrations in 
nail clippings ranged from 62 to approximately 990 pg/mg (median: 116 pg/mg) and 
from 20 to approximately 600 pg/mg (median: 56 pg/mg), respectively. R- and S-
MDA concentrations in nail clippings ranged from 2.0 to 28 pg/mg (median: 5.8 
pg/mg) and from 2.9 to 48 pg/mg (median: 6.2), respectively. By far highest R-/S-
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MDMA and R-/S-MDA concentrations were detected in the toenail clipping from 
participant no. 12 (Figure 1C, D). All nail scrapings were tested positive for R- and S-
MDMA (Figure 1E) with concentrations ranging from 4.3 to 303 pg/mg (median: 93 
pg/mg) and from 2.0 to 180 pg/mg (median: 44 pg/mg). R- and S-MDA could only be 
detected in seven of 13 scrapings at low concentrations ranging from 2.3 to 12.9 
pg/mg for both enantiomers (Figure 1F).  
There was no statistical difference in the calculated sum of concentrations of MDMA 
and MDA enantiomers in scrapings and clippings; medians were 134 and 167 pg/mg 
for MDMA, and 6.3 and 12 pg/mg for MDA, respectively (Table 2). However, the sum 
of MDMA and MDA enantiomers were significantly lower in nail samples compared to 
hair samples considering a segment length of 5 cm (Table 2). 
 
Enantiomer ratios of MDMA and MDA in hair and nail samples 
R/S-MDMA concentration ratios were higher than 1 in all hair samples (Figure 3A). 
There was no significant difference between hair segments corresponding (median: 
2.1) and not corresponding (median: 1.9) to the time of intake (Figure 3A). R/S-
MDMA concentration ratios were higher than 1 in all nail clippings and scrapings 
(medians: 2.2 and 2.4, respectively) (Figure 3A). The highest R/S-MDMA ratio of 5.7 
and 22 was observed in a hair segment and nail scraping of participant no. 1 who 
was a CYP2D6 poor metabolizer (Figure 3A).   
S-MDA was detected at slightly higher amounts in hair segments in most subjects, 
median R/S ratios were 0.84 and 0.90, respectively (Figure 3B). In nail clippings and 
scrapings, the median concentration ratios for R/S-MDA were 0.77 and 0.95, 
respectively (Figure 3B). There was no significant difference for enantiomeric ratios 
of MDMA and MDA in nail and hair samples (Figure 3). 
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Two trends of R/S-MDMA concentration ratios along the four hair segments of each 
participant were observed: decreasing (no. 1, 2, 4, 7, 11, 12, 13, 16, 17, and 18) and 
increasing (no. 6 and 10) from proximal to distal, respectively (Figure 4). There was 
no obvious trend in samples from participant no. 14 and 18 (Figure 4).  
 
Metabolite ratios of MDA to MDMA in hair and nail samples 
MDA to MDMA ratios in corresponding and not corresponding hair segments ranged 
from 0.031 to 0.074 (median: 0.047) and from 0.029 to 0.11 (median: 0.054), 
respectively (Figure 5). In nail clippings and scrapings, metabolite ratios ranged from 
0.041 to 0.13 (median: 0.055) and from 0.041 and 0.084 (median: 0.044), 
respectively (Figure 5). Overall, there was no statistical difference in metabolite 
concentration ratios of the sum of concentrations of MDA to MDMA enantiomers in 
hair segments and nail samples. 
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Discussion 
The analytical method applying chiral derivatization and LC-MS/MS analysis proved 
to be a valuable tool for the quantification of MDMA and MDA enantiomers in hair 
samples, nail scrapings and nail clippings. The samples were not tested for further 
MDMA metabolites such as DHMA and HMMA. Preliminary studies on hair samples 
positive for MDMA were negative for DHMA and negative for HMMA or only traces of 
HMMA. The method is specific and highly sensitive as low LLOQ were achieved with 
a sample weight of as low as 20 mg of hair and 5 mg of nail, respectively. In forensic 
investigations, it is often crucial to identify the time period in which a drug was taken. 
Therefore, controlled drug administration studies are needed for better understanding 
of disposition profiles into hair and nails.  
 
MDMA and MDA in hair samples 
As recently demonstrated, the time point of amphetamine intake could be estimated 
by the analysis of 0.5-cm-hair segments after controlled administration of 50 mg 
amphetamine. However, only five out of nine study participants were tested positive 
[5]. In our study, all hair samples were positive for MDMA and MDA enantiomers 
after two representative intakes of 125 mg MDMA (Table 2, Figure 1). Segmental hair 
analysis demonstrated that the highest enantiomeric (data not shown) and the 
highest calculated sum of concentrations of MDMA enantiomers (Figure 2) in hair 
segments correlated well with time of MDMA intake based on an average hair growth 
rate of 1 cm per month. However, the inter-individual variability in MDMA hair 
concentrations was large.  
In seven of the 13 participants (no. 4, 6, 11, 12, 16-18) one 1-cm-segment covered 
the time of both MDMA doses. Five participants (no. 2, 7, 10, 13, 14) received the 
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two MDMA doses with a time interval long enough to allow for monitoring by two hair 
segments (Figure 2). Intra-individual MDMA concentrations in these two hair 
segments of these participants were very similar (Figure 2, Table 2).  
The hair sample of participant no. 1 was too short to cover the time of the first MDMA 
intake (Table 2). The highest MDMA concentration (determined as outlier by Grubbs 
test, p > 0.05) was observed for subject no. 1 who was a CYP2D6 poor metabolizer 
involving a reduced elimination rate of MDMA compared to extensive metabolizers. 
The lowest sum of MDMA enantiomer concentrations was detected in a light brown 
hair sample (no. 11) (Table 2). However, there was no significant difference between 
(light) brown and dark brown hair samples in MDMA concentrations in 1-, 2- and 5-
cm-hair segments (data not shown). Also Mieczkowski and Newel who reviewed 
different data sets stated that there is no relationship of hair colour and MDMA 
concentrations in hair [40].  
For CYP2D6 extensive metabolizers, the median sum of MDMA enantiomer 
concentration in the corresponding 1-cm and the 5-cm-hair segments was 670 and 
340 pg/mg, respectively (Table 2). Applying the SoHT cut-off of 200 pg/mg for 
amphetamines [3], 12 of 13 hair samples with a 1-cm- segment and 10 of 13 hair 
samples with a 5-cm-segment would have tested positive after two representative 
MDMA intakes (each 125 mg) within a time period of about a maximum of 3 months 
(94 days, median: 42 days) (Table 2). Hair samples of participants (no. 2, 7, 10, 13, 
14) in which the two intakes were represented by two different hair segments would 
theoretically have tested positive for MDMA only after one single intake (Figure 2). 
Our findings demonstrate that the length of a hair segment should be considered for 
the interpretation of hair analysis results and application of cut-offs.  
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MDMA and MDA in nail samples and comparison to hair 
In two previous studies, it was demonstrated that a single drug dose is detectable in 
fingernail clippings [20,19]. The present study describes nail findings following two 
MDMA administrations. All nail samples were positive for MDMA enantiomers with a 
first and second administration ranging from 9 to 77 and 26 to 128 days, respectively, 
prior to sample collection. MDMA concentrations were below 500 pg/mg in all nail 
samples (Table 2). There was no relationship between drug concentrations in nail 
samples and days passed after the first or second MDMA intake. Nail incorporation 
takes place via nail matrix and nail bed [20,19]. In nail clipping drugs can be detected 
earlier after incorporation via nail bed than via nail matrix. Drugs can be detected in 
nail scrapings as soon as outgrowth of incorporated drug at the nail matrix starts 
reaching the exposed nail surface. Moreover, sweat/sebum contribute to drug 
disposition into the nail leading to drug detection already within hours after the intake.  
In most subjects, MDMA and MDA concentrations of enantiomers and their sum were 
higher in nail clippings than in scrapings (Table 2). In a recent study with cocaine 
users, cocaine concentrations were higher in scrapings compared to clippings which 
was explained by external contamination from drug residues in the environment [12]. 
In the present study, contamination can be excluded as intake was performed in the 
scope of a controlled study. Lower levels in scrapings may be explained by drug 
extraction during daily hygiene as the nail surface which is collected for scrapings is 
more exposed to drug extraction [12].  
Our study included the analysis of 13 fingernail and 3 toenail samples. In two toenail 
samples (no. 10, 16), concentrations of MDMA and MDA enantiomers and their sum 
were in the same range as in fingernail samples (Table 2). Highest MDMA and MDA 
concentrations were detected in the toenail clipping of participant no. 12. 
Interestingly, the MDMA concentration in the respective toenail scraping was not 
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significantly higher compared to other samples and also MDA was not detectable 
(Figure 1C-F, Table 2). Because toenails grow slower than fingernails [10,11,9], they 
represent a longer window of detection for drugs. Therefore, higher drug 
concentrations in toenail samples may be explained by drug use long time prior to 
the study. The 5-cm long hair sample of participant no. 12 was too short to verify this 
assumption. 
In 8 of 13 subjects, the sum of concentrations of MDMA enantiomers were lower in 
nail clippings compared to the 5-cm-hair segment, in two participants comparable 
concentrations were found (Table 2). Cirimele et al. reported for one case slightly 
higher MDMA and MDA concentrations in fingernail scrapings compared to hair [18]. 
It should be noted that hair and nail samples represent different time frames: about 5 
months based on an average growth rate if the hair sample is 5 cm long, for nail 
clippings a median window of detection of 3.5 months was determined [20]. To our 
knowledge, there is no report on windows of detection for scrapings. Further, the 
bizonal drug incorporation mechanism into nails makes time-resolved analysis 
impossible unless clippings are collected continuously over a longer period [20]. 
Despite of these limitations, our findings illustrate that nail clippings can be suitably 
used for retrospective monitoring of drug history alternatively to hair, especially in 
cases where hair is not long enough or cosmetically treated, as a positive result for 
MDMA and MDA proves MDMA intake. Nail scrapings seem less suitable as not all 
samples were positive for the metabolite MDA after two single MDMA intakes. 
 
Enantiomer ratios of MDMA and MDA in hair and nail samples 
R-MDMA concentrations were significantly higher than S-MDMA concentrations in all 
hair and nail samples whereas no difference was observed for concentrations of 
MDA enantiomers (Figure 1, Figure 3). Participant no. 1, who was a CYP2D6 poor 
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metabolizer, had the highest R/S-MDMA ratio in the hair segment corresponding to 
the time of intake and the nail scraping whereas the ratio in the nail clipping was in 
the range of the extensive CYP2D6 metabolizers (Figure 3A). To our knowledge, 
there are two reports on chiral analysis of MDMA and MDA in hair samples from 
suspected or self-declared MDMA users [41-43]. Enantiomeric ratios for MDMA and 
MDA from our controlled intake study are in concordance with hair findings reported 
by Martins et al. from a study with self-declared MDMA users after controlled MDMA 
administration [41]. Fallon et al. demonstrated that plasma and urine concentrations 
of R-MDMA exceed those of S-MDMA at all time-points analyzed over 24 h after 
administration whereas S-MDA plasma concentrations exceeded those of R-MDA 
[31]. Our study results display the same trend for hair and nail samples.  
Similar enantiomeric ratios of MDMA and MDA in hair, nail clippings and scrapings 
may suggest that drug disposition into these three matrices are comparable. 
Within subject comparison revealed two patterns for R/S-MDMA concentration ratios 
along the hair segments: a decreasing or increasing trend from proximal to distal 
segments. The decreasing and increasing trend corresponded to decreasing and 
increasing sum of concentrations of MDMA enantiomers along the hair segments, 
respectively, except for participant no. 18 (Figure 3 and 4). The highest R/S-MDMA 
ratio in the proximal (participant no.1, 12, 16, 4, 17, 2, 11,13, 7) or distal (participant 
no. 6 and 10) segments corresponded to recent or earlier MDMA administration, 
respectively (Figure 4). In case of recent MDMA intake lower R/S-MDMA ratios in 
distal segments may be explained by sweat incorporation. There was no trend for 
MDA enantiomeric ratios along the hair segments (data not shown).  
Participant no. 14 received the two MDMA doses with a time interval of 2 months, 
which was monitored by significantly increased MDMA concentrations in both 
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corresponding hair segments (Figure 2). The longer time interval of intakes resulted 
in comparable R/S-MDMA ratios along the hair segments (Figure 4B).  
 
Metabolite ratios of MDA to MDMA in hair and nail samples 
The determination of metabolite to parent drug ratios was recommended for the 
discrimination between drug intake and external contamination of a hair sample [44] 
and has proved to be useful [45-47]. For this purpose, metabolite ratios have to be 
determined after controlled intake of drug in a scope where contamination can be 
excluded. As routine analysis is typically achiral, the sum of the respective 
enantiomer concentrations were used for the metabolite ratios. In our study, median 
ratios of MDA to MDMA concentrations in hair following administration of 
pharmaceutical racemic MDMA were 0.047 in corresponding and 0.054 in not 
corresponding hair segments (Figure 5). Other authors reported similar metabolic 
ratios after street MDMA use (0.04 to 0.06) [48,49] or controlled administration (< 
0.09) [41].  
 
Conclusion 
A suitable analytical method for the chiral analysis of MDMA and MDA in hair and 
nail samples was presented. The study demonstrates that administrations of two 
representative single doses of MDMA can be detected in the hair segments 
corresponding to the time of intake and in all nail samples. As all nail clippings were 
positive for MDMA and the metabolite MDA irrespective of days passed after intake, 
clippings appears a suitable alternative to hair for prove of MDMA intake. Since no 
significant difference was observed for enantiomeric ratios in hair and nail samples 
incorporation mechanisms into both keratinized matrices may be comparable. 
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Figure 1. Measured R/S-MDMA and R/S-MDA concentrations in hair segments corresponding to 
the calculated time of intake (A+B), in nail clippings (C+D) and nail scrapings (E+F);  black circle/ 
triangle= specimen from fingernail, grey circle/ triangle= specimen from toenail. Statistical 
analysis by paired, two-tailed, non-parametric t-test; p<0.001: very significant (***),  p>0.05: not 
significant (ns).  
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Figure 2. Calculated sum of concentrations of MDMA enantiomers in four hair segments 
(1+1+1+2 cm, from proximal to distal) from participants with recent (A), earlier (participant no. 6 
and 10) and recent with earlier (participant no. 14) intake (B). Green arrows indicate hair 
segments corresponding to the time of MDMA intake. Red dotted line: SoHT cut-off for MDMA 
in hair samples. Participant no. 1 was phenotyped a CYP2D6 poor metabolizer. 
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Figure 3. Enantiomeric concentration ratios of R/S-MDMA (A) and R/S-MDA (B) in hair 
segments (seg.) corresponding (cor.) and not corresponding (not cor.) to the time of intake, 
nail clippings and scrapings; black square= fingernail, white square= toenail. Statistical 
analysis by parametric one-way ANOVA test; p>0.05: not significant (ns).  Dotted line 
represents racemic 1:1 ratio. Outlier with R/S-MDMA ratio of 5.6 and 23 (A) was phenotyped a 
CYP2D6 poor metabolizer (participant no. 1). 
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Figure 5. Metabolic ratios of sum of concentrations of MDA and MDMA enantiomers in hair 
segments corresponding (cor.) and not corresponding (not cor.) to the time of intake, nail 
clippings and scrapings; black square= fingernail, white square= toenail. Statistical analysis 
by non-paired, two-tailed, non-parametric t-test; p>0.05: not significant (ns). 
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Figure 4. Enantiomeric R/S-MDMA concentration ratios in four hair segments (1+1+1+2 cm, 
from proximal to distal) from participants with recent (A), earlier (B; no. 6 and 10) and recent 
with earlier intake (B; no. 14) intake. Green arrows indicate hair segments corresponding to the 
time of MDMA intake. Participant no. 1 was phenotyped a CYP2D6 poor metabolizer.  
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TABLES 
Table 1. Validation data for analysis of nail and hair samples. 
Analyte  
(IS) 
R-MDMA  
(R-MDMA-D5) 
S-MDMA  
(S-MDMA-D5) 
R-MDA  
(R-MDA-D5) 
S-MDA  
(S-MDA-D5) 
Hair analysis 
LOD (pg/mg) 0.125 
LLOQ (pg/mg) 0.5 
Linearity (pg/mg) 0.5; 50; 200; 300; 400; 500 
QC level LOW HIGH LOW HIGH LOW HIGH LOW HIGH 
QC conc. (pg/mg) 0.625 450 0.625 450 0.625 450 0.625 450 
Accuracy (%) -9.8 6.1 -15.9 6.7 -10.5 5.2 -1.3 -2.4 
Repeatability (%) 8.6 4.7 4.2 4.7 3.7 5.1 8.0 5.8 
Precision (%) 8.6 5.8 11.7 5.6 11.7 9.4 8.6 8.5 
ME, mean 
±SD (%) 
97 
±2.8 
114 
±3.7 
106 
±6.4 
134 
±9.8 
124 
±2.8 
127 
±7.3 
124 
±5.4 
111 
±17.6 
Nail analysis 
LOD (pg/mg) 0.5 
LLOQ (pg/mg) 2.0 
Calibrators (pg/mg) 2.0; 200; 800; 1200; 1600; 2000 
QC level LOW HIGH LOW HIGH LOW HIGH LOW HIGH 
QC conc. (pg/mg) 2.5 1800 2.5 1800 2.5 1800 2.5 1800 
Accuracy (%) 6.5 -1.8 0.1 -1.2 3.9 0.2 -6.1   2.5 
Repeatability (%) 7.4 3.7 14.3 7.5 6.3 4.2 6.1 6.8 
Precision (%) 11.2 11.8 15.0 14.9 7.5 14.3 8.5 10.6 
ME, mean  
±SD (%) 
116 
±4.1 
106 
±2.1 
126 
±6.2 
130 
±2.3 
122 
±9.4 
107 
±4.1 
113 
±14.4 
103 
±6.1 
IS= internal standard; LOD= limit of detection; LLOQ= limit of quantification; QC= Quality control; 
conc.= concentration
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Table 2. Measured concentrations of MDMA and MDA enantiomers and calculated sum of concentrations of MDMA and MDA enantiomers in hair 
segments and fingernail (and/or toenail) scrapings and clippings  
Subject 
no. 
Days 
*
1
) 
Days 
*
2
) 
Hair  
colour 
Hair segments Nail samples 
MDMA concentration (pg/mg) 
A (0-1 cm) 
proximal 
B (1-2 cm) C (2-3 cm) D (3-5 cm) 
distal 
 0-5 cm 
(calc.) 
scrapings clippings 
R S R S R S R S Sum R+S 
(calc.) 
R S Sum R+S 
 (calc.) 
R S Sum R+S 
 (calc.) 
01 (PM) 128 23 dark brown ≈3200 ≈570 ≈880 227 9.3 3.5 19 5.7 980 10 <LOQ 10 306 86 392 
02 (EM) 55 41 brown 187 90 271 134 77 41 3.7 2.2 160 8.8 2.2 11.0 105 48 153 
03 (EM) 41 14 N/A N/A 303 180 483 222 127 349 
04 (EM) 39 28 dark brown ≈1200 497 ≈610 266 303 139 151 71 650 151 214 199 91 290 
06 (EM) 94 77 dark brown 7.1 3.7 59 28 ≈550 221 478 190 310 113 44 157 127 55 182 
07 (EM) 42 17 brown 470 249 238 125 11 6.5 N/A 367 65 27 92 81 44 125 
09 (EM) 67 46 N/A N/A 4.3 2.0 6.3 103 42 145 
10 (EM) 64 49 brown 32 16 257 119 292 124 199 82 220 54*
3
) 20*
3
) 74 72*
3
) 23*
3
) 95 
11 (EM) 26 9 light brown 101 71 72 54 25 20 24 23 78 N/A 75 57 132 
12 (EM) 28 17 dark brown ≈1900 ≈860 28 18 113 77 111 70 ~640 124*
3
) 72*
3
) 196 990*
3
) 600*
3
) 1590 
13 (EM) 49 13 light brown 500 291 454 276 281 199 166 109 460 180 89 269 211 123 334 
14 (EM) 78 23 brown 242 139 76 40 331 174 40 21 210 77 34 111 70 33 103 
16 (EM) 35 14 dark brown ≈2000 ≈750 ≈950 437 60 30 19 10  ~850 74 30 104 80 27 107 
N/A 62*
3
) 20*
3
) 82 
17 (EM) 35 17 dark brown ≈680 305 ≈570 253 13 5.9 9.3 4.5 370 176 70 246 275 118 393 
18 (EM) 35 20 dark brown 206 134 148 95 9.8 5.9 7.7 5.4 120 109 62 171 288 163 451 
 MDA concentration (pg/mg) 
01 (PM) 128 23 dark brown 116 50 38 21 1.0 <LOQ 1.7 <LOQ 46 nd nd nd 20 16 36 
02 (EM) 55 41 brown 7.5 4.4 9 6.6 2.7 2.4 1.2 nd 6.7 nd nd nd 3.6 4.7 8.4 
03 (EM) 41 14 N/A N/A nd 6.2  5.8 8.2 14.0 
04 (EM) 39 28 dark brown 34 33 19 21 11 13 5.3 5.9 28 nd nd nd 6.6 8.6 15.2 
06 (EM) 94 77 dark brown <LOQ nd 3.1 2.6 19 23 14 17 16 3.5 2.8 6.3 3.6 6.0 9.6 
07 (EM) 42 17 brown 17 21 7.4 8.8 1.5 0.5 N/A 19 nd nd nd 5.7 5.1 11 
09 (EM) 67 46 N/A N/A  nd nd nd 5.3 5.2 11 
10 (EM) 64 49 brown 1.8 1.4 9.5 4.4 11 12 9.3 11 12 3.2*
3
) nd*
3
) 3.2 6.7*
3
) 6.5*
3
) 13 
11 (EM) 26 9 light brown 3.2 5.1 2.5 4.7 1.1 1.1 0.6 1.2 3.9 N/A 2.6 4.7 7.3 
12 (EM) 28 17 dark brown 58 70 1.0 <LOQ 3.9 4.3 3.4 4.0 29 nd*
3
) nd*
3
) nd*
3
) 28*
3
) 48*
3
) 76 
13 (EM) 49 13 light brown 15 26 12 23 6.9 14 3.7 5.6 21 9.5 13.2 22.7 6.5 11 18 
14 (EM) 78 23 brown 6.8 11 2.2 3.7 10 13 1.3 1.5 9.9 2.3 2.4 4.7 2.0 2.9 4.9 
16 (EM) 35 14 dark brown 96 108 40 52 3.0 4.0 1.6 1.4 61 3.8 4.3 8.1 4.9 3.5 8.4 
N/A 3.9*
3
) 3.9*
3
) 7.8 
17 (EM) 35 17 dark brown 36 39 34 32 1.0 0.8 0.7 <LOQ 29 12.9 6.4 19.3 14 19 33 
18 (EM) 35 20 dark brown 5.7 4.9 4.4 2.7 nd 0.6 nd 1.0 3.9 nd nd nd 8.6 10 19 
*
1
) Days past after first MDMA intake; *
2
) Days past after second MDMA intake; *
3
) toenail; calc.= calculated; ≈: approximately; N/A: no sample available; PM: 
phenotyped as CYP2D6 poor metabolizer; EM: phenotyped as CYP2D6 extensive metabolizer; nd: not detected; marked bold= time period of MDMA intake
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